Pfizer (NYSE:PFE) Shares Up 0.2%

Pfizer Inc. (NYSE:PFE)’s stock price rose 0.2% during mid-day trading on Tuesday . The company traded as high as $27.55 and last traded at $27.48. Approximately 6,720,455 shares changed hands during trading, a decline of 85% from the average daily volume of 43,507,957 shares. The stock had previously closed at $27.43.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Truist Financial reduced their price objective on Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Friday, March 1st. Barclays lowered their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 14th. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Finally, UBS Group dropped their price target on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research report on Thursday, December 14th. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Price Performance

The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock’s fifty day moving average price is $27.47 and its 200-day moving average price is $29.47. The firm has a market cap of $157.25 billion, a PE ratio of 77.14, a P/E/G ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period last year, the company posted $1.14 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Institutional Trading of Pfizer

A number of institutional investors have recently bought and sold shares of the company. Front Street Capital Management Inc. boosted its position in shares of Pfizer by 4.3% in the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 215 shares in the last quarter. Graves Light Lenhart Wealth Inc. lifted its holdings in shares of Pfizer by 1.4% in the second quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock valued at $729,000 after purchasing an additional 281 shares in the last quarter. Infrastructure Capital Advisors LLC grew its position in shares of Pfizer by 5.2% in the second quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 284 shares during the last quarter. Castleview Partners LLC increased its stake in shares of Pfizer by 2.4% during the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 287 shares in the last quarter. Finally, United Bank raised its position in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.